SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The ticker is trending due to significant downward price pressure and intense community debate following the circulation of a third-party statistical analysis on Reddit that downgraded the perceived probability of success for the REGAL Phase 3 trial. While many traders view the sell-off as a coordinated shakeout to clear stop-losses and accumulate shares ahead of potential clinical trial results, others are expressing concern over the lack of corporate communication during the current quiet period and the departure of prominent community members.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are facing significant volatility following better-than-expected earnings results, as investors grapple with concerns over the company's aggressive AI infrastructure spending and a pre-scheduled stock-trading plan by Chairman Larry Ellison. While some traders view the pullback as a buying opportunity given the strong revenue backlog, others remain skeptical, citing ongoing negative free cash flow and broader market uncertainty.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions is trending due to strong market enthusiasm following a triple-beat earnings report, which highlighted significant growth in revenue, bookings, and a record backlog. Traders are debating the stock's potential for further gains as a "picks and shovels" play in the AI data center infrastructure sector, with many dismissing recent price volatility as profit-taking or artificial suppression.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power shares fell sharply following a downgrade by UBS, which cited concerns over a prolonged project construction timeline, limited firm customer commitments, and significant anticipated cash burn. While retail traders debated the company's long-term potential in the nuclear energy sector, some participants expressed frustration with the stock's recent volatility and the lack of concrete commercial project announcements.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as traders analyze the impact of a share offering following strong quarterly results, with the community divided between long-term bullish sentiment based on AI growth and short-term volatility concerns driven by potential dilution and technical support levels. Competing viewpoints focus on whether the offering is a strategic balance sheet play or a signal of short-term downside, while traders closely monitor technical indicators for a potential gap fill.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore shares are trending as the company completes a major $345 million share offering, which traders see as a critical de-risking event for its balance sheet and operations. Market participants are now focused on upcoming legal catalysts, including a key hearing on the company's Santa Ynez pipeline system.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The primary catalyst for TLT is the persistent rise in Treasury yields and inflationary pressures, driven by ongoing geopolitical tensions in the Middle East and concerns over US national debt. Traders remain divided, with many expressing skepticism toward government intervention efforts like bond buybacks, while others weigh the possibility of a September rate hike against the economic impact of higher borrowing costs.

USELESS

USELESS is trending as traders speculate on its potential to hit multi-billion dollar market capitalizations, fueled by ongoing accumulation from whales and a community-driven narrative that embraces the coin's self-proclaimed "useless" nature. Supporters compare the asset's potential trajectory to historical meme coin surges, though skeptics continue to characterize the project as having no inherent value.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is experiencing volatility following a recent earnings report and subsequent decline, with traders debating whether the stock's pullback represents a buying opportunity or further downside toward lower support levels. Discussion is heavily focused on the company's long-term margin pressure, electric vehicle strategy, and potential competitive risks from Chinese manufacturers.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending following a blockbuster quarterly earnings report where the company significantly beat expectations, raised its full-year guidance, and surpassed a $1 trillion market valuation. Investors are reacting positively to surging demand for its core Mounjaro and Zepbound franchises, while discussion also focuses on the company's aggressive M&A strategy and the potential for its oral weight-loss drug to compete globally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know 

Are Medical Stocks Lagging  C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?

C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?

Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday

Vishay Intertechnology (VSH) stock up 10%, Velo3D (VELO) up 35.5%, VNET (VNET) up 32.5%, C4 Therapeutics (CCCC) up 19.4%, Kingsoft Cloud (KC) up 18.6%, Tower Semiconductor (TSEM) up 17.5%, Nebius...

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +4.76% and -5.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in 2015 and is headquartered in Watertown, MA.

C4 Therapeutics Inc

CCCC Stock Reverses Pre-Market Gains After Roche Tie-Up To Develop Cancer Treatments - Retail Sees Strong Upside

Equity

Bearish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.20	--	--	N/A
Q2 '26	-$0.23	-$0.18	20.49%	BEAT
Q1 '26	-$0.25	-$0.20	20.20%	BEAT
Q4 '25	-$0.30	-$0.18	39.02%	BEAT
Q3 '25	-$0.41	-$0.44	-8.45%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

CCCC Earnings

Upcoming Earnings: Q3 '26

Historical Earnings